Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
SEK 254.2
(1.44%)
SEK 254.2
(1.44%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 3.87 Billion SEK | 16.27% |
| 2022 | 3.33 Billion SEK | -2.69% |
| 2021 | 3.42 Billion SEK | 12.15% |
| 2020 | 3.05 Billion SEK | 72.29% |
| 2019 | 1.77 Billion SEK | 37.99% |
| 2018 | 1.28 Billion SEK | 21.92% |
| 2017 | 1.05 Billion SEK | 21.06% |
| 2016 | 870.04 Million SEK | 12.14% |
| 2015 | 775.85 Million SEK | 1.56% |
| 2014 | 763.93 Million SEK | 5.23% |
| 2013 | 725.95 Million SEK | 3.65% |
| 2012 | 700.36 Million SEK | -21.64% |
| 2011 | 893.81 Million SEK | -16.5% |
| 2010 | 1.07 Billion SEK | 85.06% |
| 2009 | 578.39 Million SEK | -1.58% |
| 2008 | 587.66 Million SEK | 594.69% |
| 2007 | 84.59 Million SEK | -47.51% |
| 2006 | 161.15 Million SEK | 27.58% |
| 2005 | 126.31 Million SEK | 50.02% |
| 2004 | 84.19 Million SEK | 25.86% |
| 2003 | 66.9 Million SEK | -64.33% |
| 2002 | 187.53 Million SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 3.99 Billion SEK | 7.05% |
| 2024 Q2 | 3.73 Billion SEK | 4.69% |
| 2024 Q1 | 3.56 Billion SEK | -8.0% |
| 2023 Q4 | 3.87 Billion SEK | -1.37% |
| 2023 Q1 | 3.66 Billion SEK | 9.9% |
| 2023 Q3 | 3.92 Billion SEK | -3.56% |
| 2023 FY | 3.87 Billion SEK | 16.27% |
| 2023 Q2 | 4.07 Billion SEK | 11.22% |
| 2022 Q1 | 3.36 Billion SEK | -1.72% |
| 2022 Q3 | 3.3 Billion SEK | -3.39% |
| 2022 Q2 | 3.42 Billion SEK | 1.75% |
| 2022 FY | 3.33 Billion SEK | -2.69% |
| 2022 Q4 | 3.33 Billion SEK | 0.73% |
| 2021 Q1 | 3.07 Billion SEK | 0.75% |
| 2021 Q4 | 3.42 Billion SEK | 6.5% |
| 2021 Q3 | 3.21 Billion SEK | -2.63% |
| 2021 Q2 | 3.3 Billion SEK | 7.35% |
| 2021 FY | 3.42 Billion SEK | 12.15% |
| 2020 FY | 3.05 Billion SEK | 72.29% |
| 2020 Q1 | 1.75 Billion SEK | -0.96% |
| 2020 Q2 | 2.14 Billion SEK | 22.28% |
| 2020 Q3 | 2.54 Billion SEK | 18.45% |
| 2020 Q4 | 3.05 Billion SEK | 20.1% |
| 2019 Q3 | 1.62 Billion SEK | 9.51% |
| 2019 FY | 1.77 Billion SEK | 37.99% |
| 2019 Q1 | 1.44 Billion SEK | 12.53% |
| 2019 Q2 | 1.48 Billion SEK | 2.56% |
| 2019 Q4 | 1.77 Billion SEK | 9.18% |
| 2018 FY | 1.28 Billion SEK | 21.92% |
| 2018 Q3 | 1.17 Billion SEK | -0.93% |
| 2018 Q2 | 1.18 Billion SEK | 11.37% |
| 2018 Q1 | 1.06 Billion SEK | 1.02% |
| 2018 Q4 | 1.28 Billion SEK | 9.38% |
| 2017 Q4 | 1.05 Billion SEK | -3.81% |
| 2017 Q3 | 1.09 Billion SEK | -2.49% |
| 2017 Q2 | 1.12 Billion SEK | 13.66% |
| 2017 Q1 | 988 Million SEK | 13.56% |
| 2017 FY | 1.05 Billion SEK | 21.06% |
| 2016 Q1 | 810 Million SEK | 4.4% |
| 2016 Q2 | 751 Million SEK | -7.28% |
| 2016 Q3 | 798 Million SEK | 6.26% |
| 2016 Q4 | 870.04 Million SEK | 9.03% |
| 2016 FY | 870.04 Million SEK | 12.14% |
| 2015 Q2 | 742 Million SEK | -3.01% |
| 2015 FY | 775.85 Million SEK | 1.56% |
| 2015 Q3 | 758 Million SEK | 2.16% |
| 2015 Q4 | 775.85 Million SEK | 2.36% |
| 2015 Q1 | 765 Million SEK | 0.14% |
| 2014 Q1 | 678.4 Million SEK | -6.55% |
| 2014 Q3 | 725.5 Million SEK | -0.47% |
| 2014 Q4 | 763.93 Million SEK | 5.3% |
| 2014 FY | 763.93 Million SEK | 5.23% |
| 2014 Q2 | 728.9 Million SEK | 7.44% |
| 2013 Q1 | 681.2 Million SEK | -2.74% |
| 2013 FY | 725.95 Million SEK | 3.65% |
| 2013 Q4 | 725.95 Million SEK | 4.71% |
| 2013 Q3 | 693.3 Million SEK | -1.44% |
| 2013 Q2 | 703.4 Million SEK | 3.26% |
| 2012 Q1 | 829.8 Million SEK | -7.16% |
| 2012 Q2 | 810.5 Million SEK | -2.33% |
| 2012 Q3 | 742.3 Million SEK | -8.41% |
| 2012 Q4 | 700.36 Million SEK | -5.65% |
| 2012 FY | 700.36 Million SEK | -21.64% |
| 2011 FY | 893.81 Million SEK | -16.5% |
| 2011 Q1 | 1 Billion SEK | -6.46% |
| 2011 Q2 | 1 Billion SEK | 0.74% |
| 2011 Q3 | 953.2 Million SEK | -5.49% |
| 2011 Q4 | 893.81 Million SEK | -6.23% |
| 2010 FY | 1.07 Billion SEK | 85.06% |
| 2010 Q4 | 1.07 Billion SEK | -0.06% |
| 2010 Q3 | 1.07 Billion SEK | 7.67% |
| 2010 Q2 | 994.7 Million SEK | 48.31% |
| 2010 Q1 | 670.7 Million SEK | 15.96% |
| 2009 Q4 | 578.39 Million SEK | 0.0% |
| 2009 FY | 578.39 Million SEK | -1.58% |
| 2008 FY | 587.66 Million SEK | 594.69% |
| 2007 FY | 84.59 Million SEK | -47.51% |
| 2006 FY | 161.15 Million SEK | 27.58% |
| 2005 FY | 126.31 Million SEK | 50.02% |
| 2004 FY | 84.19 Million SEK | 25.86% |
| 2003 FY | 66.9 Million SEK | -64.33% |
| 2002 FY | 187.53 Million SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AcuCort AB | -1.09 Million SEK | 352602.275% |
| AlzeCure Pharma AB (publ) | -2508.00 SEK | 154465809.729% |
| BioGaia AB (publ) | 181.2 Million SEK | -2037.922% |
| Enzymatica AB (publ) | 11.49 Million SEK | -33589.886% |
| Enorama Pharma AB (publ) | 4.29 Million SEK | -90160.951% |
| Gabather AB (publ) | -1772.00 SEK | 218623124.831% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | 7.11 Million SEK | -54348.349% |
| Nanexa AB (publ) | 1.91 Million SEK | -202621.088% |
| Newbury Pharmaceuticals AB (publ) | 4.99 Million SEK | -77457.558% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 42.4 Million SEK | -9036.792% |
| Probi AB (publ) | 116.7 Million SEK | -3219.481% |
| Swedencare AB (publ) | 398.1 Million SEK | -873.122% |
| Toleranzia AB | -1.34 Million SEK | 289204.478% |
| Vivesto AB | - SEK | -Infinity% |